Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials.
OBJECTIVE
Despite a robust clinical trial enterprise and encouraging phase II results, the vast minority of oncologic drugs in development receive regulatory approval. In addition, clinicians occasionally make therapeutic decisions based on phase II data. Therefore, clinicians, investigators, and regulatory agencies require improved understanding of the implications of positive phase II studies. We hypothesized that prior probability of eventual drug approval was significantly different across GI cancers, with substantial ramifications for the predictive value of phase II studies.


METHODS
We conducted a systematic search of phase II studies conducted between 1999 and 2004 and compared studies against US Food and Drug Administration and National Cancer Institute databases of approved indications for drugs tested in those studies.


RESULTS
In all, 317 phase II trials were identified and followed for a median of 12.5 years. Following completion of phase III studies, eventual new drug application approval rates varied from 0% (zero of 45) in pancreatic adenocarcinoma to 34.8% (24 of 69) for colon adenocarcinoma. The proportion of drugs eventually approved was correlated with the disease under study (P < .001). The median type I error for all published trials was 0.05, and the median type II error was 0.1, with minimal variation. By using the observed median type I error for each disease, phase II studies have positive predictive values ranging from less than 1% to 90%, depending on primary site of the cancer.


CONCLUSIONS
Phase II trials in different GI malignancies have distinct prior probabilities of drug approval, yielding quantitatively and qualitatively different predictive values with similar statistical designs. Incorporation of prior probability into trial design may allow for more effective design and interpretation of phase II studies.
All authors: The University of Texas MD Anderson Cancer Center.
Daniel M
DM
Halperin
All authors: The University of Texas MD Anderson Cancer Center.
J Jack
JJ
Lee
All authors: The University of Texas MD Anderson Cancer Center.
Cecile Gonzales
CG
Dagohoy
All authors: The University of Texas MD Anderson Cancer Center. jyao@mdanderson.org.
James C
JC
Yao
D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D011336:Probability; D012107:Research Design